Shionogi & Co., Ltd.
↗Osaka, Japan
Shionogi & Co., Ltd. is a leading Japanese pharmaceutical company headquartered in Osaka, Japan. Founded in 1878, the company has a long-standing history of innovation, particularly in the fields of infectious diseases, central nervous system (CNS) disorders, and pain management. Shionogi is globally recognized for its research-driven approach and its significant contributions to the development of blockbuster drugs, often through strategic partnerships with global pharma giants.
The company's current strategic focus is defined by its 'SHIONOGI Group Vision,' which aims to evolve from a traditional pharmaceutical company into a 'Healthcare Service Provider.' This involves expanding beyond drug discovery into diagnostics and digital health. Shionogi is particularly prominent in the HIV space through its joint venture with ViiV Healthcare (alongside GSK and Pfizer) and has recently gained international attention for its rapid development of COVID-19 therapeutics and vaccines.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Infectious Diseases & CNS Therapeutics
SIZE & FINANCIALS
Employees:5001-10000
Revenue:$3B-$4B
Founded:1878
Ownership:public
Status:operating
FUNDING
Stage:Pre-IPO
Investors:The Master Trust Bank of Japan, Custody Bank of Japan, Sumitomo Life Insurance Company
STOCK
Exchange:TYO
Ticker:4507
Market Cap:$13.5B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial (Xocova, Fetroja, Dovato)
Modalities:Small molecule, Vaccines, Peptides, Antibodies
Active Trials:45
Trial Phases:Phase 1: 18 | Phase 2: 15 | Phase 3: 10 | Phase 4: 2
FDA Approvals:12
EMA Approvals:10
CORPORATE STRUCTURE
Subsidiaries:Shionogi Inc. (USA), Shionogi B.V. (Europe), C&O Pharmaceutical Technology
Key Partnerships:ViiV Healthcare (HIV collaboration with GSK/Pfizer), Roche (Xofluza marketing), MSD (Gardasil distribution in Japan)
COMPETITION
Position:Leader
Competitors:Takeda Pharmaceutical, Astellas Pharma, Daiichi Sankyo, Eisai, Pfizer, Merck & Co.
LEADERSHIP
Key Executives:
Isao Teshirogi - CEO & President
John Keller - Senior Executive Officer, Head of West Commercial
Board Members:Isao Teshirogi, Hiroshi Ozaki, Keiichi Ando
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Shionogi & Co., Ltd.. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.